Advanced search
Publication Cover
Journal of Pain & Palliative Care Pharmacotherapy Volume 38, 2024 - Issue 2
Submit an article Journal homepage
116
Views
0
CrossRef citations to date
0
Altmetric
Case Reports

Subcutaneous Bolus Infusions of Undiluted Levetiracetam for End-of-Life Patients: Two Cases

Kenneth Skova Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark;b Department of Clinical Medicine, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
View further author information
&
Astrid Lyagerc Palliative Unit, Department of Oncology and Palliative Medicine, Zealand University Hospital, Roskilde, DenmarkView further author information
Pages 138-142 | Received 28 Sep 2023, Accepted 23 Jan 2024, Published online: 12 Feb 2024

References

  • European Medicines Agency. European Medicines Agency. EMEA/H/C/000277 - WS2339/G - Keppra: EPAR - product information. Available from: https://www.ema.europa.eu/documents/product-information/keppra-epar-product-information_en.pdf. Accessed September 28, 2023.
  • Sutherland A, Meldon C, Harrison T, Miller M. Subcutaneous levetiracetam for the management of seizures at the end of life: an audit and updated literature review. J Palliat Med. 2021;24(7):976–981. doi:10.1089/jpm.2020.0414.
  • Papa P, Oricchio F, Ginés M, Maldonado C, Tashjian A, Ibarra M, Percovich M, Fagiolino P, Pedragosa B, Vázquez M, et al. Pharmacokinetics of subcutaneous levetiracetam in palliative care patients. J Palliat Med. 2021;24(2):248–251. doi:10.1089/jpm.2019.0525.
  • Usery JB, Michael LM, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol. 2010;99(2):251–260. doi:10.1007/s11060-010-0126-8.
  • Murray-Brown FL, Stewart A. Remember Keppra: seizure control with subcutaneous levetiracetam infusion. BMJ Support Palliat Care. 2016;6(1):12–13. doi:10.1136/bmjspcare-2016-001102.
  • Rémi C, Lorenzl S, Vyhnalek B, Rastorfer K, Feddersen B. Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects. J Pain Palliat Care Pharmacother. 2014;28(4):371–377. doi:10.3109/15360288.2014.959234.
  • Furtado I, Gonçalves F, Gonçalves J, Neves J. Continuous subcutaneous levetiracetam in end-of-life care. BMJ Case Rep. 2018;2018:bcr-2017-222340. doi:10.1136/bcr-2017-222340.
  • Kondasinghe JS, Look ML, Moffat P, Bradley K. Subcutaneous levetiracetam and sodium valproate use in palliative care patients. J Pain Palliat Care Pharmacother. 2022;36(4):228–232. doi:10.1080/15360288.2022.2107145.
  • Gaviria-Carrillo M, Mora-Muñoz L, Diaz-Forero AF, Vargas-Osorio J, Torres-Ballesteros V, Estrada J, Vélez Van Meerbeke A, Rodríguez JH. Experience of subcutaneous levetiracetam in palliative care. Med Princ Pract. 2023;32(1):90–95. doi:10.1159/000529461.
  • Westphal S, Hertler C, Blum D, Schettle M. Subcutaneous levetiracetam application sustains therapeutic drug levels. Palliat Med Rep. 2021;2(1):157–159. doi:10.1089/pmr.2020.0119.
  • Cuellar-Valencia L, Claros-Hulbert A, Ortegon A, Pino J, Velandia L, Correa-Morales JE. Subcutaneous levetiracetam administration in Latino patients on home care. Am J Hosp Palliat Care. 2023:10499091231212450. doi:10.1177/10499091231212450.
  • Más-Sesé G, Martín-Bautista D, Navarro-Catalá A. Experience of using subcutaneous levetiracetam in palliative patients. Neurologia. 2021;36(6):474–475. doi:10.1016/j.nrl.2020.06.017.
  • Monteiro RL, Moreira JG, Barroso J, Oliveira JE, Gonçalves E. Letter to the editor: use of subcutaneous levetiracetam in palliative care. J Palliat Med. 2022;25(7):1019–1020. doi:10.1089/jpm.2022.0175.
  • European Medicines Agency. European Medicines Agency. EMEA/H/C/277/X/46: EPAR - scientific discussion - extension. Available from: https://www.ema.europa.eu/documents/scientific-discussion-variation/keppra-h-c-277-x-0046-epar-scientific-discussion-extension_en.pdf. Accessed September 28, 2023.
  • Morgan O, Medenwald B. Safety and tolerability of rapid administration undiluted levetiracetam. Neurocrit Care. 2020;32(1):131–4. doi:10.1007/s12028-019-00708-5.
  • Wheless JW, Clarke D, Hovinga CA, Ellis M, Durmeier M, McGregor A, Perkins F. Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study. J Child Neurol. 2009;24(8):946–51. doi:10.1177/0883073808331351.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.